MDGL madrigalpharma.com Net earnings per share for the last 12 months

Public company logo of Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals (MDGL) is expanding the production of therapies for metabolic liver pathologies in the US, leveraging the first approved drug in the niche. The company's 12-month profit per unit reflects asset dynamics, where the -5.97 mark indicates the yield level. Market capitalization is based on exclusive sales of Rezdiffra, creating a monopoly ecosystem for NASH treatment under FDA supervision.

MDGL (Madrigal Corp) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/16/2026

Analytical breakdowns and data insights for company Madrigal Corp (MDGL)

- stock price and consensus target price:
Fundamental company valuation:Madrigal Pharmaceuticals Inc (MDGL)
Mass-produced product of Madrigal Pharma

Annual net earnings per share aggregate the final financial result distributed across the total volume of issuance, allowing for an assessment of the real return on each ownership stake. By analyzing the 12-month rolling EPS, an investor can benchmark the efficiency of Madrigal Pharmaceuticals (MDGL) against its competitors, given that the production outsourcing model via SLA contracts minimizes capital expenditures, directly impacting final profitability.

Competitors of Madrigal Pharmaceuticals

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Corcept|RYTM (Rhythm Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|AKRO: Earnings per share for the last four quarters|MTSR (Metsera Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MoonLake Immunotherapeutics|Net earnings per share (EPS TTM) CRNX|Earnings per share for the last twelve months NAMS (NewAmsterdam Pharma Company)|Earnings per share for the last twelve months soleno.life SLNO|Amicus Corp (FOLD) - Net earnings per one share for the last twelve months|ETNB - Earnings per share for the last twelve months|AGIO: Earnings per share for the last twelve months|GPCR: Net earnings per share (EPS TTM)|MDXG - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Rezolute Bio|Lexicon Corp (LXRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months mbxbio.com (MBX)|Net earnings per share (EPS TTM) altimmune.com (ALT)|Net earnings per share (EPS TTM) AARD (aardvarktherapeutics.com)|Net earnings per share for the last four quarters Sagimet Biosciences Inc. (SGMT)|BioAge Labs, Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Biomea Fusion Corp BMEA|QNCX: Net earnings per share (EPS TTM)|Fractyl Health, Inc. (GUTS) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months VTVT|Agape ATP Corporation - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) PLUR|SYBX - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) LPCN (lipocine.com)|Net earnings per share (EPS TTM) Matinas BioPharma MTNB|SPRB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Galecto Corp|CTCX (Carmell Corp) - Net earnings per share for the last 12 months|Lumos Pharma Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months ONVO|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS